Carl Johann Hansen

Carl Johann Hansen

Auto-generated profile, based on publicly available information

Carl Johann Hansen

Department of Cardiology, Copenhagen University Hospital Rigshospitalet , 2100 Copenhagen

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
PWPeder E Warming
Peder E Warming
RGRodrigue Garcia
Rodrigue Garcia
CHCarl J Hansen
Carl J Hansen
SSSami O Simons
Sami O Simons
CTChristian Torp-Pedersen
Christian Torp-Pedersen
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
Chronic obstructive pulmonary disease (COPD) is present in 13% of atrial fibrillation (AF) patients. In patients diagnosed with both AF and COPD, we aimed to assess overall mortality risk and its association with temporal sequence in AF and COPD diagnosis. This nationwide study assessed all patients aged 18–85 years diagnosed with both COPD and AF between 1999 and 2018 in Denmark. Three groups were defined according to the temporal sequence of diagnosis: COPD diagnosed at least 6 months before AF (COPD-First), AF diagnosed at least 6 months before COPD (AF-First) and COPD, and AF diagnosed within a 6-months’ time frame (AF∼COPD). We included 62 806 patients (75.0 years; 56.5% males). After 5 years of follow-up, 31 494 (50.1%) died. Mortality was highest in the COPD-First group (COPD-First: 52.8%; AF-First: 46.0%; AF∼COPD 50.6%). In a multivariable Cox-regression model adjusted for age, sex, type 2 diabetes, history of acute myocardial infarction, hypertension, heart failure, dyslipidemia, cancer, chronic kidney disease, and stroke, the AF∼COPD group (HR 1.19, 95% CI 1.16–1.23; P < 0.001) and COPD-First group (HR 1.30, 95% CI 1.27–1.33; P < 0.001) had a higher risk of death compared with the AF-First group. A restricted cubic spline analysis showed that the earlier the COPD was diagnosed, the worse is the prognosis. Patients with concomitant AF and COPD had a very poor prognosis and the temporal sequence in diagnosis was differentially associated with prognosis, where a COPD diagnosis preceding an AF diagnosis was accompanied with a higher mortality risk compared with a COPD diagnosis following an AF diagnosis. Key question: What is mortality burden and its association with temporal sequence in diagnosis in patients with both AF and COPD? Key finding: In patients with AF and COPD, mortality exceeded 50% after 5 years of follow-up. In this population, those diagnosed with COPD first had the worst outcomes. Take home message: These results should reinforce the need for multidisciplinary approaches between cardiologists and pulmonologists to ensure the best treatment in this high-risk patient population.

25 February 2025 in Circulation
Verified
Journal Article
Closed access
CHCarl Johann Hansen
Carl Johann Hansen
JSJesper Svane
Jesper Svane
PWPeder Emil Warming
Peder Emil Warming
TLThomas Hadberg Lynge
Thomas Hadberg Lynge
RGRodrigue Garcia
Rodrigue Garcia
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
BACKGROUND: Declining cardiovascular mortality rates have been well-documented, yet temporal trends of sudden cardiac death (SCD) in young individuals remain unclear. We provide contemporary nationwide estimates of the temporal trends of SCD in young individuals (1–35 years of age) from 2000 through 2019 and correlate these trends to changes in out-of-hospital cardiac arrest (OHCA) patterns, rates of inherited cardiac diseases, and implantations of implantable cardioverter defibrillators (ICD). METHODS: All individuals between 1 and 35 years of age living in Denmark from 2000 through 2019 were included, with annual re-evaluation of the at-risk population in regard to age. Adjudication of SCD cases relied on multiple sources, including death certificates, medical files, and autopsy reports. Information on OHCA, diagnostic rates, and ICD implantations were captured from nationwide administrative registries. Annual incidence rates of SCD were calculated, and temporal trends in SCD incidence were computed as percentage change annualized. Trends in OHCA survival and characteristics, diagnostic rates of inherited cardiac diseases, and ICD implantations were assessed. RESULTS: During the 20-year study period (47.5 million person-years), 1057 SCDs were identified (median age, 29 years; 69% male). The overall incidence of SCD was 2.2 per 100 000 person-years and declined by 3.31% (95% CI, 2.42–4.20) annually, corresponding to a 49% (95% CI, 38.7–57.6) reduction during the study. Rates of witnessed SCD declined markedly (percentage change annualized −7.03% [95% CI, −8.57 to −5.48]), but we observed no changes in the rate of unwitnessed SCD (percentage change annualized −0.09% [95% CI, −1.48 to 1.31]). Therefore, the proportion of unwitnessed SCD increased by 79% ( P <0.001). Survival after OHCA in young individuals (1 to 35 years of age) increased from 3.9% to 28%, mainly because of increased bystander cardiopulmonary resuscitation and defibrillation rates. Diagnostic rates of inherited cardiac diseases increased 10-fold (incidence rate ratio, 10.4 [95% CI, 8.46–12.90]) and the ICD implantation rate increased 2-fold (incidence rate ratio, 1.97 [95% CI, 1.51–2.60]). CONCLUSIONS: SCD incidence rates in young individuals declined by 49% over the past 2 decades. The decline was paralleled by improved survival of OHCA, higher diagnostic rates of inherited cardiac diseases, and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.

20 December 2023 in JACC: Clinical Electrophysiology
Verified
Journal Article
Open access
CHCarl J. Hansen
Carl J. Hansen
JSJesper Svane
Jesper Svane
MPMarie K. Palsøe
Marie K. Palsøe
JIJulia C. Isbister
Julia C. Isbister
EPElizabeth Paratz
Elizabeth Paratz
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
Knowledge of toxicological findings among sports-related sudden cardiac death (SrSCD) is scarce. This study aimed to describe postmortem toxicology findings in a multinational cohort of young SrSCD. Patients with sudden cardiac death (SCD) aged 12 to 49 years with a complete post mortem were included from Denmark, Spain, and Australia. Postmortem findings were compared between SrSCD and non-SrSCD, and toxicology findings in SrSCD were assessed. We included 3,189 SCD, of which 219 (7%) were sports-related. SrSCD patients were younger (36 years vs 41 years; P < 0.001) and of male predominance (96% vs 75%; P < 0.001), and their death was more often caused by structural cardiac disease (68% vs 61%; P = 0.038). Positive toxicology screenings were significantly less likely among SrSCD than non-SrSCD (12% vs 43%; P < 0.001), corresponding to 82% lower odds of a positive toxicology screening in SrSCD. Patient characteristics were similar between SrSCDs with positive and negative toxicology screenings, but deaths were more often unexplained (59% vs 34%). Nonopioid analgesics were the most common finding (3%), and SCD-associated drugs were detected in 6% of SrSCD. SUD was more prevalent among the SrSCD with positive toxicology (59% vs 34%). Sports-related SCD mainly occurred in younger men with structural heart disease. They had a significantly lower prevalence of a positive toxicology screening compared with non-SrSCD, and detection of SCD-associated drugs was rare.

13 July 2023 in Heart Rhythm
Verified
Journal Article
Closed access
CHCarl Johann Hansen
Carl Johann Hansen
JSJesper Svane
Jesper Svane
TLThomas Hadberg Lynge
Thomas Hadberg Lynge
NSNiels Kjær Stampe
Niels Kjær Stampe
PBPriya Bhardwaj
Priya Bhardwaj
BWBo Gregers Winkel
Bo Gregers Winkel

14 July 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
RGRodrigue Garcia
Rodrigue Garcia
PWPeder Emil Warming
Peder Emil Warming
CHCarl Johann Hansen
Carl Johann Hansen
DRDeepthi Rajan
Deepthi Rajan
CTChristian Torp-Pedersen
Christian Torp-Pedersen
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
Background: Little data exist on the risk and outcomes of out-of-hospital cardiac arrest (OHCA) in people with HIV (PWH). We aimed to describe OHCA in PWH as compared with the general population in terms of incidence, characteristics, and survival. Methods: This nationwide study assessed all individuals aged 18–85 years between 2001 and 2019 in Denmark. The cumulative incidence of OHCA was computed using cause-specific Cox models accounting for competing risk of death. Results: Among 6 565 309 individuals, 6 925 (median age: 36; interquartile range [IQR]: 28–44 y; 74% males) were infected at some point with HIV. The incidence of OHCA was 149 (95% CI: 123–180)/100 000 person-years in PWH versus 64 (95% CI: 64–65)/100 000 person-years in people without HIV (P < .001). Age at the time of cardiac arrest was 52 (IQR: 44–61) years in PWH versus 69 (IQR: 59–77) years in individuals without HIV (P < .001). In a multivariable model adjusted for age, sex, hypertension, diabetes, heart failure, ischemic heart disease, atrial fibrillation, chronic obstructive pulmonary disease, cancer, and renal failure, PWH had a 2-fold higher risk of OHCA (hazard ratio: 2.84; 95% CI: 2.36–3.43; P < .001). Thirty-day mortality (89% vs 88%; P = .80) was comparable to individuals without HIV. Conclusions: HIV is an independent risk factor for OHCA, and those who experience OHCA with HIV are much younger than those without HIV. Almost 90% of PWH died 1 month after OHCA. Further research should strive to find out how to reduce OHCA occurrence in this population.

4 April 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CJCamilla H. B. Jespersen
Camilla H. B. Jespersen
JKJohanna Krøll
Johanna Krøll
PBPriya Bhardwaj
Priya Bhardwaj
CHCarl Johann Hansen
Carl Johann Hansen
JSJesper Svane
Jesper Svane
PWPeter E. Weeke
Peter E. Weeke
Background: Patients with Brugada syndrome (BrS) are recommended to avoid drugs that may increase their risk of arrhythmic events. We examined treatment with such drugs in patients with BrS after their diagnosis. Methods and Results: All Danish patients diagnosed with BrS (2006–2018) with >12 months of follow‐up were identified from nationwide registries. Nonrecommended BrS drugs were grouped into drugs to “avoid” or “preferably avoid” according to http://www.brugadadrugs.org . Cox proportional hazards analyses were performed to identify factors associated with any nonrecommended BrS drug use, and logistic regression analyses were performed to examine associated risk of appropriate implantable cardioverter defibrillator therapy, mortality, and a combined end point indicating an arrhythmic event of delayed implantable cardioverter defibrillator implantation, appropriate implantable cardioverter defibrillator therapy, and mortality. During a median follow‐up of 6.8 years, 93/270 (34.4%) patients with BrS (70.4% male, median age at diagnosis 46.1 years [interquartile range, 32.6–57.4]) were treated with ≥1 nonrecommended BrS drugs. No difference in any nonrecommended BrS drug use was identified comparing time before BrS diagnosis (12.6%) with each of the 5 years following BrS diagnosis ( P >0.05). Factors associated with any nonrecommended BrS drug use after diagnosis were female sex (hazard ratio [HR]) 1.83 [95% CI, 1.15–2.90]), psychiatric disease (HR, 3.63 [1.89–6.99]), and prior use of any nonrecommended BrS drug (HR, 4.76 [2.45–9.25]). No significant association between any nonrecommended BrS drug use and implantable cardioverter defibrillator therapy (n=20/97, odds ratio [OR], 0.7 [0.2–2.4]), mortality (n=10/270, OR, 3.4 [0.7–19.6]), or the combined end point (n=38/270, OR, 1.7 [0.8–3.7]) was identified. Conclusions: One in 3 patients with BrS were treated with a nonrecommended BrS drug after BrS diagnosis, and a BrS diagnosis did not change prescription patterns. More awareness of nonrecommended drug use among patients with BrS is needed.